Biological Assembly 1  

 3D View: Structure | Electron Density | Ligand Interaction

Standalone Viewers  
Protein Workshop | Ligand Explorer

Global Symmetry: Asymmetric - C1 
Global Stoichiometry: Monomer - A 

Biological assembly 1 assigned by authors.

Macromolecule Content

• Total Structure Weight: 34217.73 
• Atom Count: 2415 
• Residue Count: 298 
• Unique protein chains: 1

1PF8

Crystal Structure of Human Cyclin-Dependent Kinase 2 Complexed with a Nucleoside Inhibitor

• DOI: 10.2210/pdb1PF8/pdb

• Classification: TRANSFERASE
• Organism(s): Homo sapiens
• Expression System: Spodoptera frugiperda


• Deposited: 2003-05-24 Released: 2003-12-23 
• Deposition Author(s): Moshinsky, D.J., Bellamacina, R.C., Boisvert, D.C., Huang, P., Hui, T., Jancarik, J., Kim, S.H., Rice, A.G.

---

Experimental Data Snapshot

• Method: X-RAY DIFFRACTION
• Resolution: 2.51 Å
• R-Value Free: 0.306 
• R-Value Work: 0.208 

Literature

SU9516: biochemical analysis of cdk inhibition and crystal structure in complex with cdk2.

Moshinsky, D.J., Bellamacina, C.R., Boisvert, D.C., Huang, P., Hui, T., Jancarik, J., Kim, S.H., Rice, A.G.

(2003) Biochem.Biophys.Res.Commun. 310: 1026-1031

• PubMed: 14550307 


• PubMed Abstract: 
  

SU9516 is a 3-substituted indolinone compound with demonstrated potent and selective inhibition toward cyclin dependent kinases (cdks). Here, we describe the kinetic characterization of this inhibition with respect to cdk2, 1, and 4, along with the crystal structure in complex with cdk2. The molecule is competitive with respect to ATP for cdk2/cyclin A, with a K(i) value of 0.031 microM. Similarly, SU9516 inhibits cdk2/cyclin E and cdk1/cyclin B1 in an ATP-competitive manner, although at a 2- to 8-fold reduced potency. In contrast, the compound exhibited non-competitive inhibition with respect to ATP toward cdk4/cyclin D1, with a 45-fold reduced potency. The X-ray crystal structure of SU9516 bound to cdk2 revealed interactions between the molecule and Leu83 and Glu81 of the kinase. This study should aid in the development of more potent and selective cdk inhibitors for potential therapeutic agents.

---

Organizational Affiliation: 

SUGEN, Inc., South San Francisco, CA 94080, USA. [e-mail]

Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
Molecule	Chains	Sequence Length	Organism	Details
Cell division protein kinase 2	A	298	Homo sapiens	Mutation(s): 0  Gene Names: CDK2 (CDKN2) EC: 2.7.11.22
Find proteins for P24941 (Homo sapiens) Go to Gene View: CDK2 Go to UniProtKB:  P24941

Small Molecules

Ligands 1 Unique
ID	Chains	Name / Formula / InChI Key	2D Diagram & Interactions
SU9	A	(3Z)-3-(1H-IMIDAZOL-5-YLMETHYLENE)-5-METHOXY-1H-INDOL-2(3H)-ONE SU9516 C13 H11 N3 O2 QNUKRWAIZMBVCU-WCIBSUBMSA-N

External Ligand Annotations
ID	Binding Affinity (Sequence Identity %)
SU9	IC50: 22 - 35 nM (100) BINDINGDB
SU9	Ki: 31 nM PDBBIND

Experimental Data & Validation

Experimental Data

• Method: X-RAY DIFFRACTION
• Resolution: 2.51 Å
• R-Value Free: 0.306 
• R-Value Work: 0.208 
• Space Group: P 2₁ 2₁ 2₁

Unit Cell:

Length (Å)	Angle (°)
a = 53.753	α = 90.00
b = 72.306	β = 90.00
c = 71.944	γ = 90.00

Software Package:

Software Name	Purpose
SCALEPACK	data scaling
DENZO	data reduction
GLRF	phasing
X-PLOR	refinement

Structure Validation

Entry History 

Deposition Data

• Deposited Date: 2003-05-24 
• Released Date: 2003-12-23 
• Deposition Author(s): Moshinsky, D.J., Bellamacina, R.C., Boisvert, D.C., Huang, P., Hui, T., Jancarik, J., Kim, S.H., Rice, A.G.

Revision History 

• Version 1.0: 2003-12-23
  Type: Initial release
• Version 1.1: 2008-04-29
  Type: Version format compliance
• Version 1.2: 2011-07-13
  Type: Version format compliance
• Version 1.3: 2014-04-16
  Type: Data collection